ID: ALA3354684

Max Phase: Preclinical

Molecular Formula: C36H44N8O6S

Molecular Weight: 716.86

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)c1nc2ccccc2s1

Standard InChI:  InChI=1S/C36H44N8O6S/c1-20(2)30(34(50)41-27(7-5-17-40-36(38)39)31(47)35-43-26-6-3-4-8-29(26)51-35)44-33(49)28(19-22-11-15-24(46)16-12-22)42-32(48)25(37)18-21-9-13-23(45)14-10-21/h3-4,6,8-16,20,25,27-28,30,45-46H,5,7,17-19,37H2,1-2H3,(H,41,50)(H,42,48)(H,44,49)(H4,38,39,40)/t25-,27-,28-,30-/m0/s1

Standard InChI Key:  IBLAVZWCQYPXLH-RLAGABBFSA-N

Associated Targets(Human)

Matriptase 677 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Transmembrane protease serine 6 209 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Plasma 6361 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 716.86Molecular Weight (Monoisotopic): 716.3105AlogP: 2.08#Rotatable Bonds: 17
Polar Surface Area: 245.64Molecular Species: BASEHBA: 10HBD: 9
#RO5 Violations: 2HBA (Lipinski): 14HBD (Lipinski): 11#RO5 Violations (Lipinski): 3
CX Acidic pKa: 9.20CX Basic pKa: 11.57CX LogP: 1.97CX LogD: 0.30
Aromatic Rings: 4Heavy Atoms: 51QED Weighted: 0.03Np Likeness Score: -0.14

References

1. Duchêne D, Colombo E, Désilets A, Boudreault PL, Leduc R, Marsault E, Najmanovich R..  (2014)  Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2.,  57  (23): [PMID:25387268] [10.1021/jm5015633]
2. St-Georges C, Désilets A, Béliveau F, Ghinet M, Dion SP, Colombo É, Boudreault PL, Najmanovich RJ, Leduc R, Marsault É..  (2017)  Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.,  129  [PMID:28219045] [10.1016/j.ejmech.2017.02.006]

Source